Saturday 17 October 2026
Export NVOS’s income statement to Excel — free account
Novo Integrated Sciences, Inc.
NVOS Healthcare Medical Care Facilities
Novo Integrated Sciences, Inc.’s revenue for fiscal 2024 (year ended August 2024) was $13.3 million, up 5.75% from fiscal 2023. Revenue growth for five consecutive years.
0.00
0.00
NaN
Follow NVOS
| Older periods | Nov '23 | Feb '24 | May '24 | Aug '24 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 98.44 | 0.00 | 0.00 |
P/S ratio |
1.54 | 0.81 | 1.45 | 0.39 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.33) | (6.49) | (29.82) | (9.58) | |
P/B ratio |
0.86 | 0.51 | 2.03 | 0.36 | |
Price to Tangible BV |
802.86 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.50 | 0.84 | 1.42 | 0.41 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.74) | (2.33) | (4.03) | (1.08) | |
EV/FCF |
(4.68) | (2.31) | (3.99) | (1.06) | |
Quick Ratio |
0.49 | 0.39 | 0.21 | 0.27 | |
Current Ratio |
0.62 | 0.50 | 0.27 | 0.37 | |
Net Debt/EBITDA |
0.34 | 2.94 | (0.50) | (0.35) | |
Debt/Assets |
2.88% | 3.07% | 3.02% | 3.33% | |
Debt/Equity |
0.05 | 0.05 | 0.11 | 0.07 | |
Asset Turnover |
0.35 | 0.38 | 0.38 | 0.39 | |
Operating CF/Net income |
0.46 | 0.62 | 0.05 | (0.11) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(23.14) | (11.10) | (14.13) | (14.06) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
135.22% | 90.33% | 108.41% | 81.60% | |
Intangible Assets out of Total Assets |
0.62 | 0.65 | 0.63 | 0.62 | |
Share Based Compensation of Revenue |
30.72% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.36) | (0.72) | (0.99) | (2.32) | |
Graham Number |
0.00 | 0.42 | 0.00 | 0.00 | |
Earnings Yield |
(36.13%) | 1.02% | (60.34%) | (300.00%) | |
Free Cash Flow Yield |
(20.75%) | (44.98%) | (24.48%) | (97.99%) | |
Revenue per Share |
0.23 | 0.18 | 0.17 | 0.17 | |
Operating CF per Share |
(0.13) | (0.10) | (0.04) | (0.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.13) | (0.10) | (0.04) | (0.03) | |
Cash per Share |
0.10 | 0.04 | 0.08 | 0.05 | |
Shareholders Equity per Share |
1.39 | 1.24 | 0.52 | 0.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.39 | 1.24 | 0.52 | 0.81 | |
Free Cash Flow |
(2.15) | (1.71) | (0.66) | (0.55) | |
Working Capital |
(4.11) | (4.94) | (16.52) | (9.16) | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
(7.15) | (8.04) | (19.50) | (12.11) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.85 | 2.59 | 2.83 | 2.84 | |
Average Payables |
2.74 | 2.11 | 2.90 | 3.37 | |
Average Inventory |
1.14 | 0.94 | 1.03 | 1.05 | |
Average Assets |
37.50 | 35.72 | 35.54 | 33.85 | |
Average Common Equity |
21.98 | 24.43 | 17.98 | 19.56 |
Columns are period end dates